Adaptive Biotechnologies Launches immunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool for SARS-CoV-2

Tailored for vaccine developers to accurately and reproducibly measure and track COVID-19 specific T-cell response in clinical trials

Powered by T-cell immune response data from over 1,000 COVID-19 patients from ImmuneCODE, the largest public database mapping T-cell receptors (TCRs) to SARS-CoV-2

New data demonstrates T-cell response persists beyond 90 days

SEATTLE, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies (Nasdaq: ADPT) announced today the launch of immunoSEQ T-MAP COVID, a proprietary research product and data analysis service to accurately and reproducibly measure the T-cell immune response to vaccines in development and track the persistence of that response over time. This product leverages data by Snyder et al., made available today that map T cells from over 1,000 patients to specific SARS-CoV-2 antigens that elicit an immune response. These data also demonstrate that SARS-CoV-2-specific T cells are persisting in recovered patients for over 90 days, adding important information to the ongoing effort to define immunity to COVID-19. These results are powered by ImmuneCODE, a groundbreaking open database developed with partner Microsoft, to share the population-wide T-cell immune response to the COVID-19 virus with the research community. An abstract detailing the methodology behind ImmuneCODE, including the most recent database release, is available and the manuscript is currently undergoing peer review for future publication.

“The critical role of the T-cell response is increasingly becoming a focus of attention. While antibodies have been a mainstay of measuring the immune response to vaccines, for COVID-19, it is becoming clear that the T-cell response is necessary for a complete picture of immunity,” said Harlan Robins, Chief Scientific Officer and co-founder. “Adaptive’s proven immune medicine platform is designed for the quantitative sequencing and mapping of T cells at scale from a simple blood draw and can be incorporated seamlessly into clinical trials.”

immunoSEQ T-MAP COVID provides researchers with a quantitative map of T-cell receptors (TCRs) and SARS-CoV-2 antigens that are driving the immune response to vaccines and other therapies in development for COVID-19. This reproducible, high-throughput, high resolution, molecular data will be made available through Adaptive’s existing cloud-based immunoSEQ Analyzer to assist with analysis and visualization of the immune response.